tbuckley/cabot-search huggingface dataset:
FRI0698-HPR A RANDOMISED CONTROLLED CLINICAL TRIAL COMPARING THE EFFECTIVENESS OF 6 AND 12 WEEKS OF A SHOULDER SPECIFIC EXERCISE PROGRAMME FOR PATIENTS WITH ROTATOR CUFF RELATED SHOULDER PAIN
Authors: Sandra Keyes, Noreen Walsh, Mark Phelan
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Research has shown loaded exercise to be beneficial for patients with rotator cuff related shoulder pain in terms of improving shoulder function, self-reported disability and pain<sup>1,2</sup>. The optimal duration for which these patients should complete a loaded exercise programme to achieve beneficial effects remains unclear. <h3>Objectives</h3> The purpose of this study is to determine if 6 weeks of a supervised shoulder specific exercise programme is as effective as 12 weeks of the same programme, for improving shoulder function, self-reported disability and pain, in patients with rotator cuff related shoulder pain. <h3>Methods</h3> In this randomised controlled single-blinded study patients with a history of lateral upper arm pain with MRI confirmation of rotator cuff pathology or positive testing on a cluster of clinical rotator cuff tests were included. Patients with a recent history of shoulder surgery or a shoulder fracture were excluded. Participants were randomly assigned to complete either 6 weeks (short group) or 12 weeks (long group) of the exercise programme. Both groups performed the same specific set of loaded exercises daily at home and attended 6 clinic-based group exercise sessions<sup>2</sup>. Participants were assessed at 6 weeks, 3 and 6 months. Shoulder function was assessed using the Constant-Murley (CM) score. Disability was assessed using the QuickDash and the Shoulder Pain and Disability Index (SPADI). Pain was assessed using a visual analogue scale. Group comparisons were made using univariate generalised linear models. <h3>Results</h3> 85 patients were included in this study as per Table 1. Within each group shoulder function, self-reported disability and pain improved significantly at 3 months (<i>p</i> &lt; .05). Comparisons at 3 months showed the long group had significantly lower pain scores (<i>p</i> = .02). At 3 months there was no significant difference between the two groups in the CM score (<i>p</i> = .415), SPADI score (<i>p</i> = .053) and QuickDash score (<i>p</i> = .245). However, at 6 months, the long group had significantly greater changes in both the CM score (<i>p</i> = .007) and the SPADI score (<i>p</i> = .002). <h3>Conclusion</h3> In the management of patients with rotator cuff related shoulder pain the findings of this study indicate that a 12 week exercise programme results in better outcomes for pain at 3 months and self-disability and shoulder function at 6 months. <h3>References</h3> [1] Littlewood C, et al. Exercise for rotator cuff tendinopathy: A systematic review. Physiotherapy. 2012; 98(2), 101 - 109. [2] Holmgren T, et al. Effect of specific exercise strategy on need for surgery in patients with subacromial impingement syndrome: randomised controlled study. Br J Sports Med. 2014; 48(19), 1456-1457. <h3>Disclosure of Interests</h3> None declared
AB0849 CAUSES OF EARLY MORTALITY IN PATIENTS WITH OSTEOPOROTIC HIP FRACTURES
Authors: Tatiana Raskina, Julia Averkieva, Tatiana Protasova, Inessa Grigoreva
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Osteoporosis (OP) is a skeletal disorder characterized by compromised bone strength, which predisposes the individual to an increased risk of fractures of the hip, spine, and other skeletal sites. OP, a major public health problem, is becoming increasingly prevalent with the world population and occupies a leading place in the structure of morbidity and mortality. <h3>Objectives</h3> To study the causes of mortality in patients with hip osteoporotic fractures during 6 months after injury. <h3>Methods</h3> 432 patients with osteoporotic hip fractures were under observation. During the study, mortality rates were assessed both in hospital and during the first 6 months after the fracture. The main causes of mortality were tracked by ICD-10 classes. Information about fractures and their outcomes was obtained from data from the archives of the trauma departments of Kemerovo, city registry offices, telephone interviews of patients and their relatives. <h3>Results</h3> In the first 6 months after injury, 95 out of 432 patients died. Overall mortality was 22.0%. In the group of deceased patients, females prevailed: 73 women (16.5%) and 22 men (5.1%) (χ<sup>2</sup> = 4.4; p &lt;0.0001). It was established that 6 months after a hip fracture in 63 (66.3%) patients, death occurred from cardiovascular system diseases: in men - 13 (59.0%) cases and in women - 50 (68.4%) (p = 0.9). Respiratory diseases, as the cause of death, were detected in 18 (18.9%) patients (in men - 5 (22.9%) cases and in women - 13 (17.8%) (p = 0.1)), oncological diseases - in 10 (10.5%) men and women: 2 (9.1%) and 8 (10.9%) cases, respectively (p = 0.5). Diseases of the digestive system accounted for a small percentage of the total number of deaths (3.2%), without statistically significant differences by gender (1 (4.5%) case for men and 2 (2.9%) cases for women (p = 0.75)). Among the dead men, 1 (1.1%) death was caused by an infectious disease. <h3>Conclusion</h3> During all periods of observation, most of the deceased men and women had cardiovascular and respiratory diseases. <h3>Reference</h3> <h3>Disclosure of Interests</h3> None declared
Abstract 15568: Body Mass Index in Young Women and Risk of Cardiovascular Disease and Mortality
Authors: Pigi Dikaiou, Martin Adiels, Lena Björck, Karin Manhem, Annika Rosengren
Journal: Circulation (2018)

Introduction: Although the impact of obesity on younger age groups of women has attracted attention owing to observations of increased morbidity and mortality, little is known regarding the associa...
Regarding Marcia
Authors: Avital Y. O'Glasser
Journal: Annals of Internal Medicine (2019)

On Being a Patient5 March 2019Regarding MarciaAvital Y. O'Glasser, MDAvital Y. O'Glasser, MDOregon Health & Science University, Portland, Oregon (A.Y.O.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-2837 Audio Reading - “Regarding Marcia” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Regarding Marcia," by A.Y. O'Glasser. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail “Reverse her DNR status.”I couldn't believe those words had just come out of my mouth.I had taken another telephone call from my father-in-law about my 88-year-old grandmother-in-law, Marcia. But had I actually just said that?The day before, Marcia notified us that she was sitting in the emergency room with chest pain. She had coronary disease with prior stent placement, but for a decade she had done well on her optimized geriatric regimen.I first met Marcia 14 years before, after my husband and I started dating in college. Although at that point my own grandparents were clearly ... Author, Article, and Disclosure InformationAffiliations: Oregon Health & Science University, Portland, Oregon (A.Y.O.)Corresponding Author: Avital Y. O'Glasser, MD, Oregon Health & Science University, Department of Medicine, Division of Hospital Medicine, 3181 SW Sam Jackson Park Road, Mail Code BTE 119, Portland, OR 97239; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Regarding Marcia” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Regarding Marcia," by A.Y. O'Glasser. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 5 March 2019Volume 170, Issue 5Page: 346-347KeywordsCatheterizationDyspneaGeriatricsHip fracturesHospital medicineIschemiaPatient advocacyQuality of lifeStent implantationStroke ePublished: 5 March 2019 Issue Published: 5 March 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
PS1103 NOVEL COMPOUND HETEROZYGOUS MUTATIONS CAUSING FACTOR XI DEFICIENCY IN UNRELATED TWO CHINESE PATIENTS
Authors: Q. Li, R. Zhou
Journal: HemaSphere (2019)

Background: Coagulation factor XI deficiency is a rare bleeding disorder, whose molecular mechanism is not well understood. Aims: To investigate the molecular pathogenesis of coagulation factor XI (FXI) deficiency in two unrelated Chinese patients Methods: The diagnosis was validated by coagulant assays: APTT and correct test, PT and coagulation factors activities. The patients’ DNA were extracted and all exons and flanking sequences of FXI gene were amplified using PCR. After purified, the products were sequenced directly, the mutations were detected by comparing with wild sequences and analysed using some bioinformatics software. Results: The two patients were diagnosed as coagulation factor XI deficiency due to prolonged APTT, corrected APTT and low activities of coagulation factor FXI. The results of APTT, corrected APTT and FXI:C were 88.1 s, 32.9 s,1.1% and 107.1 s, 31.5 s, 3.8% for patient1 and patient2, respectively. Genetic analysis showed compound heterozygous mutations g.1251–1G&gt;A and g.1271delT in patient1 and the sequencing results of TA plasmid clones found that the two mutations were located on different single strands of chromosomes. Double heterozygous mutations g.1070A&gt;G and g.1446C&gt;G were detected in patient2 resulting in Lys357Arg and Cys482Stop. Software analysis suggested the mutations probably brought amino acid sequence changed, protein features affected and splice site changed. Summary/Conclusion: Double heterozygous mutations g.1251–1G&gt;A, g.1271delT and g.1070A&gt;G, g.1446C&gt;G had been identified in unrelated two coagulation factor XI deficiency Chinese patients, which might be the reasons for their prolonged APTT and low FXI:C. To the best of our knowledge, the four mutations are reported firstly in literature.
Abstract 18473: Filling a β-blocker in the Week After Discharge for a Heart Failure Hospitalization is Associated With a Lower Risk of Rehospitalization Among Medicare Beneficiaries
Authors: Emily B Levitan, Melissa K Van Dyke, Ligong Chen, Raegan W Durant, Todd M Brown, Monika M Safford, Meredith L Kilgore
Journal: Circulation (2015)

Introduction: In clinical trial populations with heart failure (HF) and reduced ejection fraction, there is evidence that the β-blockers metoprolol succinate, carvedilol, and bisoprolol reduce mortality and hospitalizations. The short-term impact of β-blockers among typical hospitalized HF patients with heavy comorbidity burdens is less clear. Hypothesis: Filling a β-blocker within 7 days of HF hospitalization is associated with lower rehospitalization risk 8-30 days after discharge. Methods: We identified 76,568 HF hospitalizations in the Medicare national 5% sample among beneficiaries with fee-for-service and medication coverage (20,358 with documented systolic dysfunction). Beneficiary characteristics, β-blocker fills, and rehospitalization for HF, cardiovascular disease (CVD), or any cause were assessed through Medicare claims. We used generalized estimating equations to calculate multivariable-adjusted risk ratios for rehospitalization. Results: The average age was 76 years, 61% were women, and 19% were black. Comorbidities were common (hypertension 85%, coronary heart disease 70%, chronic kidney disease 65%, chronic obstructive pulmonary disease 57%, diabetes 53%, atrial fibrillation 48%, depression 25%, hypotension 21%, valvular or rheumatic heart disease 15%). Almost all had prior diagnoses of HF (99%). Within 7 days of discharge, 25% filled any β-blocker and 17% filled metoprolol succinate, carvedilol, or bisoprolol. In the 8-30 days following discharge, 9% were rehospitalized for HF, 12% for CVD, and 22% for any cause. Filling a β-blocker was associated with a lower risk rehospitalization for HF, CVD, and any cause in both the overall population and the subgroup with documented systolic dysfunction ( Table ). Conclusions: Medicare beneficiaries with HF who filled β-blockers shortly after discharge had better short-term prognosis; however, risk of rehospitalization among those with and without β-blocker fills was high.
PS982 THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA
Authors: P. Aigner, T. Mizutani, J. Horvath, V. Just, H. Sill, F. Grebien, R. Moriggl, E. Casanova, D. Stoiber
Journal: HemaSphere (2019)

Background: Signal transducer and activator of transcription 3 (STAT3) plays a central role in proliferation, differentiation and oncogenic transformation. It is expressed in two alternatively spliced isoforms, STAT3α and truncated STAT3β, which lacks the C‐terminal transactivation domain and instead carries seven unique amino acids. Interestingly, STAT3β recently gained attention as a powerful anti‐tumorigenic molecule and protective prognostic marker. This has been shown in patients with esophageal squamous cell carcinoma as well as in mouse models for breast, skin and colon cancer. Deregulated STAT3 signaling is frequently observed in leukemogenesis and generally associated with a poor clinical outcome in patients with acute myeloid leukemia (AML). In addition, it has been shown that the expression ratios of STAT3α and STAT3β change upon myeloid differentiation. However, the exact role of STAT3β in AML patients and during disease progression remains unknown. Aims: The goal of our study is to analyze the contribution of the two STAT3 isoforms to leukemogenesis with a particular focus on STAT3β in AML development. Methods: We analyzed more than 50 AML patient samples for STAT3β/STAT3α mRNA expression levels and its correlation with clinical prognosis and overall survival. Furthermore, we generated an inducible Stat3β transgenic mouse model and crossed it with Pten ‐deficient mice, a previously described model for AML. In addition, we used fetal liver‐derived stem cells from Stat3β transgenic mice, transduced with a retrovirus encoding for the MLL‐AF9 translocation, in a transplant model for AML. Results: We observed a correlation between clinical prognosis and STAT3β/STAT3α expression ratio. A higher STAT3β/STAT3α ratio was further associated with a favorable clinical prognosis and a significantly increased overall survival. In both in vivo mouse models we could demonstrate that the expression of STAT3β impairs leukemogenesis and leukemic cell infiltration into hematopoietic organs. The STAT3β‐dependent delay in disease progression and leukemic infiltration resulted in a significant increase of overall survival. Summary/Conclusion: In summary, the results of our study demonstrate STAT3β as an anti‐tumorigenic molecule in AML mouse models and the STAT3β/STAT3α ratio in AML patient derived blasts positively correlates with survival.
Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases–11
Authors: Luciana Kase Tanno, Robert Chalmers, Ana Luiza Bierrenbach, F. Estelle R. Simons, Bryan Martin, Nicolas Molinari, Isabella Annesi-Maesano, Margitta Worm, Victoria Cardona, Nikolaos G. Papadopoulos, Mario Sanchez-Borges, Lanny J. Rosenwasser, Ignacio Ansontegui, Motohiro Ebisawa, Juan Carlos Sisul, Edgardo Jares, Maximiliano Gomez, Ioana Agache, Peter Hellings, Antonella Muraro, Francis Thien, Ruby Pawankar, James L. Sublett, Thomas Casale, Pascal Demoly
Journal: Journal of Allergy and Clinical Immunology (2019)
Suicide Rates Among Adolescents and Young Adults in the United States, 2000-2017
Authors: Oren Miron, Kun-Hsing Yu, Rachel Wilf-Miron, Isaac S. Kohane
Journal: JAMA (2019)

This study uses Centers for Disease Control and Prevention (CDC) data to characterize trends in suicide rates among adolescents and young adults aged 15 to 24 years in the United States and to determine if the increase in suicide rates observed in years 2000-2016 is continuing.
Are smokers “hardening” or rather “softening”? An ecological and multilevel analysis across 28 European Union countries
Authors: Ariadna Feliu, Esteve Fernandez, Cristina Martinez, Filippos T. Filippidis
Journal: European Respiratory Journal (2019)

Tobacco control policies can reduce smoking prevalence. These measures may be less effective where smoking prevalence has significantly declined, as the remaining smokers have "hardened". Our aim was to empirically evaluate the "hardening hypothesis" at the population level in the European Union (EU) and explore factors associated with hardcore smoking.We conducted two separate analyses in the EU using data on smoking from the Eurobarometer surveys (2009-2017, n=112 745). 1) A panel-data fixed-effects linear regression to investigate changes over time in the percentage of hardcore smokers in relation to standardised smoking prevalence at the country level. 2) A multilevel logistic regression analysis with hardcore (daily smokers, ≥15 cigarettes per day who have not attempted to quit in the last 12 months) or light (<5 cigarettes per day) smoking as the dependent variable and time as the main independent variable, controlling for individual and ecological variables.We studied 29 010 current smokers (43.8% hardcore smokers and 14.7% light smokers). The prevalence of hardcore smoking among adult smokers increased by 0.55 (95% CI 0.14-0.96) percentage points per each additional percentage point in the overall smoking prevalence. The odds of being a hardcore smoker increased over time and were higher in middle-aged males and people with financial difficulties, while the odds of being a light smoker significantly declined among females.This study does not support the "hardening hypothesis" in the EU between 2009 and 2017, but suggests a softening of the smoking population. Existing tobacco control policies are likely to be suitable to further decrease smoking prevalence in Europe.
Abstract 18739: Goal-RCT: Results From the First Randomized Trial Comparing Colesevelam vs. Ezetimibe in Type 2 Diabetes
Authors: Harpreet S Bajaj, Ruth E Brown, Dishay S Jiandani, Karri Venn, Akshay Jain, Hani Al Asaad, Hasnain Khandwala, Suzan Abdel-Salam, Ronnie Aronson
Journal: Circulation (2017)

Introduction: Additional lipid-lowering therapies are often added to statin drugs in patients with type 2 diabetes (T2D) who fail to achieve target LDL. Our objective was to compare the efficacy an...
Mitigation of monocyte driven thrombosis on cobalt chrome surfaces in contact with whole blood by thin film polar/hydrophobic/ionic polyurethane coatings
Authors: Audrey Gossart, Didier Letourneur, Adeline Gand, Véronique Regnault, Mohamed Amine Ben Mlouka, Pascal Cosette, Emmanuel Pauthe, Véronique Ollivier, J. Paul Santerre
Journal: Biomaterials (2019)
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Authors: Elizabeth J. Carey, Jennifer C. Lai, Christopher Sonnenday, Elliot B. Tapper, Puneeta Tandon, Andres Duarte‐Rojo, Michael A. Dunn, Cynthia Tsien, Eric R. Kallwitz, Vicky Ng, Srinivasan Dasarathy, Matthew Kappus, Mustafa R. Bashir, Aldo J. Montano‐Loza
Journal: Hepatology (2019)

Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut‐off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best‐studied technique for assessing sarcopenia in patients with cirrhosis. Cut‐off values for sarcopenia, defined as SMI &lt; 50 cm 2 /m 2 in male and &lt; 39 cm 2 /m 2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review
Authors: Niccolò Giaj-Levra, Matteo Giaj-Levra, Valerie Durieux, Silvia Novello, Benjamin Besse, Baktiar Hasan, Lizza E. Hendriks, Antonin Levy, Anne-Marie C. Dingemans, Thierry Berghmans
Journal: Journal of Thoracic Oncology (2019)
Abstract 13917: Valsalva Maneuver: An Essential Diagnostic Tool or Life Threatening Maneuver? Rare Case of Intraprocedural Spontaneous Coronary Perforation in a Hypertrophic Cardiomyopathy Patient
Authors: Prabhakaran P Gopalakrishnan, Sharan Rufus, Muhammad R Sardar
Journal: Circulation (2017)

Introduction: We describe the first reported instance of spontaneous coronary artery perforation after valsalva maneuver in a hypertrophic obstructive cardiomyopathy (HOCM) patient. Case Presentati...